Paradigm Biopharmaceuticals Phase 3 Knee Drug Trial Fails Interim Test

Phase 3 interim result falls short of continuation threshold

Paradigm Biopharmaceuticals (ASX: PAR) has confirmed that the independent Data Safety Monitoring Board (DSMB) determined the interim efficacy result for its Phase 3 PARAOA012 trial did not reach the pre-specified threshold required for the study to continue. The trial, evaluating injectable pentosan polysulfate sodium (iPPS/Zilosul®) for knee osteoarthritis, therefore met the study’s pre-specified futility criterion.

The planned interim analysis was conducted after approximately 50% of participants had reached the Day 112 primary efficacy endpoint, with 538 participants treated across the trial. The observed treatment effect fell below the minimum efficacy threshold required for continuation under the study’s statistical design.

The interim analysis was triggered after the trial reached the 50% dosing milestone in March 2026, at which point the study had enrolled participants across sites in Australia, the United States, Hong Kong, and Moldova, with real-time daily pain recordings serving as the primary endpoint to reduce placebo response variability.

Paradigm has requested that its securities remain in voluntary suspension under ASX Listing Rule 17.2 while it assesses the financial implications of the outcome. The company expects to provide a further announcement addressing its funding arrangements and the implications for future operations by 28 September 2026.

Missing data and operational challenges at the centre of the outcome

Operational challenges during the conduct of the trial resulted in a significant amount of missing data, which the company states has impacted the interim efficacy results. Under the statistical analysis plan, missing data is imputed, and this imputation affected the efficacy outcome.

Paradigm’s blinded personnel remain blinded to treatment allocation, the actual treatment effect size, and the underlying treatment-group results. The DSMB reviewed unblinded data independently of the company’s internal teams.

Paradigm has stated it will work with the DSMB, its clinical partners, and investigators to determine the appropriate remaining study activities and database processes. Following completion of the required database and unblinding processes, the company will undertake a detailed review of available Phase 3 data, covering pain, function, safety, and other pre-specified endpoints. The company continues to review the available data to better understand the nature and extent of the missing data’s impact.

Executive Chairman Paul Rennie

“The Board and the entire Paradigm team are deeply disappointed by this outcome. We recognise the disappointment it brings to our shareholders and everyone who has supported the program. An initial review, by Paradigm’s unblinded clinical staff, identified missing data. Under the statistical analysis plan, missing data is imputed and this imputation impacted the efficacy outcome. This is very disappointing given our broad and positive experience with iPPS in treating osteoarthritis. We remain optimistic in the therapeutic potential of PPS in treating osteoarthritis.”

“PARAOA012 treated 538 participants. We are continuing to review the available data to gain further information and better understand the impact of the operational challenges and missing data.”

What is a Phase 3 futility analysis?

Clinical drug development follows a structured sequence of trial phases before a therapy can be submitted for regulatory approval. Each phase serves a distinct purpose:

1. Phase 1 — Small-scale safety testing in healthy volunteers or patients to assess tolerability and dosing.
2. Phase 2 — Mid-size trials examining early efficacy signals and further safety data in the target patient population.
3. Phase 3 — Large-scale, controlled trials designed to confirm efficacy and safety before a regulatory submission.
4. Regulatory submission — The sponsor submits trial data to a regulatory authority (such as the US FDA) for review and potential approval.

PARAOA012 was a Phase 3 trial.

Most large Phase 3 trials include a pre-planned interim futility analysis, a scheduled checkpoint at which an independent board reviews accumulating data to assess whether continuing the trial remains statistically justified. If the observed treatment effect at that point falls below a pre-set minimum threshold, the study is deemed unlikely to meet its primary endpoint at the final analysis. This is a built-in stopping rule, designed to avoid exposing participants to further risk in a trial that statistical modelling suggests will not succeed.

The Data Safety Monitoring Board (DSMB) is an independent body, with no affiliation to the sponsor company, that reviews unblinded trial data on behalf of participants and trial integrity. Its role is to make objective, data-driven recommendations about whether a trial should continue, pause, or stop.

In Paradigm’s case, the DSMB confirmed the interim result met the pre-specified futility criterion, triggering the study’s discontinuation threshold.

Financial position, IP portfolio, and path forward

The ASX announcement is explicit: material uncertainty remains regarding the financial and operational consequences of the trial outcome and the path forward for the company. The Board’s assessment is ongoing, and Paradigm is not yet able to quantify the full impact on its funding requirements and future operations.

The Board is currently reviewing the following:

• Potential trial wind-down costs
• Remaining contractual commitments
• Future funding requirements
• The company’s rights and obligations under its existing funding arrangements

Paradigm is working closely with Obsidian Global GP, LLC, its secured convertible note facility provider, to assess the implications of the trial outcome under the facility and the options available to the company. Discussions are ongoing, and the company has stated it cannot be certain of their outcome or when that outcome will be known.

Paradigm retains a substantial intellectual property portfolio and is assessing the most appropriate path forward. Notably, the Zilosul® osteoarthritis program retains Fast Track designation from the US Food and Drug Administration (FDA). Any future clinical or regulatory development strategy will be determined after consideration of the Phase 3 dataset and, where appropriate, discussions with regulatory authorities.

The Board has committed to providing a further update by 28 September 2026 addressing funding arrangements and the implications for future operations.

For investors assessing the company’s remaining resources ahead of the 28 September 2026 update, our detailed coverage of Paradigm’s pre-result financial position walks through the $5.75 million R&D tax refund received in July 2026, the pro forma cash balance, and the four operational workstreams management had prioritised as recently as weeks before the futility determination.

Don’t Miss the Next Healthcare Breakthrough

Big News Blast delivers FREE breaking ASX healthcare news to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button to start receiving alerts the moment market-moving news breaks.